Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00238719|
Recruitment Status : Completed
First Posted : October 13, 2005
Last Update Posted : May 19, 2006
|Condition or disease||Intervention/treatment||Phase|
|Social Anxiety Disorder||Drug: Venlafaxine ER||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||293 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder|
|Study Start Date :||December 1999|
|Estimated Study Completion Date :||June 2003|
- Final on therapy Social Anxiety Scale-Adolescents and Children (SAS-AC) total score.
- Response, defined as a score of 1 (very much improved) or (very improved), on the Clinical Global Impressions-Improvement (CGI-I) scale; Final on therapy Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-AC) total score.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00238719
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|